Shanghai Hutchison Pharmaceuticals Limited
Clinical trials sponsored by Shanghai Hutchison Pharmaceuticals Limited, explained in plain language.
Now part of
HUTCHMED (China) Limited
HCM
NASDAQ
Develops and commercializes oncology and immunology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to boost stroke recovery in major trial Results expected Jun 2027 (estimated)